E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma

Medicina (Lithuania)

Volumn 51, Issue 1, 2015, Pages 1-9

  Bielskiene, Kristina ^a   Bagdoniene, Lida ^b   Mozuraitiene, Julija ^a   Kazbariene, Birute ^a   Janulionis, Ernestas ^a  

^a NATIONAL CANCER INSTITUTE   (Lithuania)

^b VILNIUS UNIVERSITY   (Lithuania)

Author keywords

F box proteins; Melanoma; RING proteins; SCF E3 ligases; Ubiquitin ligases

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; F BOX PROTEIN; TUMOR MARKER; UBIQUITIN PROTEIN LIGASE;

ANTAGONISTS AND INHIBITORS; DRUG DESIGN; DRUG EFFECTS; ENZYME SPECIFICITY; ENZYMOLOGY; HUMAN; MELANOMA; METABOLISM; MOLECULARLY TARGETED THERAPY; PROGNOSIS; PROTEIN DEGRADATION; SKIN NEOPLASMS; UBIQUITINATION;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; DRUG DESIGN; ENZYME INHIBITORS; F-BOX PROTEINS; HUMANS; MELANOMA; MOLECULAR TARGETED THERAPY; PROGNOSIS; PROTEOLYSIS; SKIN NEOPLASMS; SUBSTRATE SPECIFICITY; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84940041307     PISSN: 1010660X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.medici.2015.01.007     Document Type: Review

References (84)

1. Komander D., Michael R. The ubiquitin code. Annu Rev Biochem 2012, 81:203-229.
2. Xu P., Duong D.M., Seyfried N.T., Cheng D., Xie Y., Robert J., et al. Quantitative proteomics reveals the function of unconventional ubiquitin chains in proteasomal degradation. Cell 2009, 137:133-145.
3. Shimizu Y., Okuda-Shimizu Y., Hendershot L.M. Ubiquitylation of an ERAD substrate occurs on multiple types of amino acids. Mol Cell 2010, 40:917-926.
4. Moretti J., Brou Ch. Ubiquitinations in the Notch signaling pathway. Int J Mol Sci 2013, 14:6359-6381.
5. Fraile J.M., Quesada V., Rodriguez D., Freije J.M.P., Lopez-Otin L. Deubiquitinases in cancer: new functions and therapeutic options. Oncogene 2012, 31:2373-2388.
6. Nakayama K. Growth and progression of melanoma and non-melanoma skin cancers regulated by ubiquitination. Pigment Cell Melanoma Res 2010, 23:338-351.
7. Lipkowitz S., Weissman A.M. RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat Rev Cancer 2011, 11:629-644.
8. Sun Y., Li H. Functional characterization of SAG/RBX2/ROC2/RNF7, an antioxidant protein and an E3 ubiquitin ligase. Protein Cell 2013, 4(2):103-116.
9. Wenzel D.M., Klevit R.E. Following Ariadne's thread: a new perspective on RBR ubiquitin ligases. BMC Biol 2012, 10:24.
10. Lorenz S., Cantor A.J., Rape M., Kuriyan J. Macromolecular juggling by ubiquitylation enzymes. BMC Biol 2013, 11:65.
11. Jianping J., Cardozo T., Lovering R.C., Elledge S.J., Pagano M., Harper J.W. Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev 2004, 18:2573-2580.
12. Xie C., Wei W., Sun Y. Role of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases in skin cancer. J Genet Genomics 2013, 40:97e106.
13. Fuchs S.Y., Spiegelman V.S., Kumar K.G. The many faces of beta-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer. Oncogene 2004, 23:2028-2036.
14. Bucheit A.D., Syklawer E., Jakob J.A., Bassett R.L., Curry J.L., Gershenwald J.E., et al. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer 2013, 119(21):3821-3829.
15. Liu S., Yamauchi H. p27-Associated G1 arrest induced by hinokitiol in human malignant melanoma cells is mediated via down-regulation of pRb, Skp2 ubiquitin ligase, and impairment of Cdk2 function. Cancer Lett 2009, 286:240-249.
16. Vaid M., Prasad R., Sun Q., Katiyar S.K. Silymarin targets beta catenin signaling in blocking migration/invasion of human melanoma cells. PLoS ONE 2011, 6:e23000.
17. Hershko D.D. Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer. Cancer 2008, 112:1415-1424.
18. Wu L., Grigoryan A., Li Y., Hao B., Pagano M., Cardozo T. Specific small molecule inhibitors of Skp2-mediated p27. Chem Biol 2012, 19(12):1515-1524.
19. Chen G., Cheng Y., Martinka M., Li G. Cytoplasmic Skp2 expression is increased in human melanoma and correlated with patient survival. PLoS ONE 2011, 6(2):e17578. PMID: 21386910.
20. Li Q., Murphy M., Ross J., Sheehan C., Carlson J.A. Skp2 and p27 kip1 expression in melanocytic nevi and melanoma: an inverse relationship. J Cutan Pathol 2004, 31:633-642.
21. Rose A.E., Wang G., Hanniford D., Monni S., Tu T., Shapiro R., et al. Clinical relevance of SKP2 alterations in metastatic melanoma. Pigment Cell Melanoma Res 2011, 24(1):197-206.
22. Sumimoto H., Hirata K., Yamagata S., Miyoshi H., Miyagishi M., Taira K., et al. Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi. Int J Cancer 2006, 118:472-476.
23. Rico-Bautista E., Yang C.C., Lu L., Roth G.P., Wolf D.A. Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells. BMC Biol 2010, 8:153.
24. Qu X., Shen L., Zheng Y., Cui Y., Feng Z., Liuand F., et al. A signal transduction pathway from TGF-β1 to SKP2 via Akt1 and c-Myc and its correlation with progression in human melanoma. J Invest Dermatol 2014, 134:159-167.
25. Cheng Y., Li G. Role of the ubiquitin ligase Fbw7 in cancer progression. Cancer Metastasis Rev 2012, 31:75-87.
26. Busino L., Millman S.E., Scotto L., Kyratsous C.A., Basrur V., O'Connor O., et al. Fbxw7a- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat Cell Biol 2012, 14(4):375-385.
27. Wang Z., Inuzuka H., Zhong J., Wan L., Fukushima H., Sarkar F., et al. Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett 2012, 586:1409-1418.
28. Zhou W., Wei W., Sun Y. Genetically engineered mouse models for functional studies. Cell Res 2013, 23:599-619.
29. Welcker M., Clurman B. FBW7 ubiquitin ligase a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 2008, 8:83-93.
30. Bhaskaran N., van Drogen F., Ng H.F., Kumar R., Ekholm-Reed S., Peter M., et al. Fbw7α and Fbw7γ collaborate to shuttle cyclin E1 into the nucleolus for multiubiquitylation. Mol Cell Biol 2013, 33(1):85-97.
31. Welcker M., Larimore E.A., Swanger J., Bengoechea-Alonso M.T., Grim J.E., Ericsson J., et al. Fbw7 dimerization determines the specificity and robustness of substrate degradation. Genes Dev 2013, 27:2531-2536.
32. Tan Y., Sangfelt O., Spruck C. The Fbxw7/hCdc4 tumor suppressor in human cancer. Cancer Lett 2008, 271:1-12.
33. Ishikawa Y., Hosogane M., Okuyama R., Aoyama S., Onoyama I., Nakayama K.I., et al. Opposing functions of Fbxw7 in keratinocyte growth, differentiation and skin tumorigenesis mediated through negative regulation of c-Myc and Notch. Oncogene 2013, 32(15):1921-1932.
34. O'Neil J., Grim J., Strack P., Rao S., Tibbitts D., Winter Ch., et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors. J Exp Med 2007, 204(8):1813-1824.
35. Lerner M., Lundgren J., Akhoondi S., Jahn A., Ng H.F., Moqadam F.A., et al. MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression. Cell Cycle 2011, 10:2172-2183.
36. Cheng Y., Chen G., Martinka M., Ho V., Li G. Prognostic significance of Fbw7 in human melanoma and its role in cell migration. J Invest Dermatol 2013, 133(7):1794-1802.
37. Li J., Cheng Y., Tai D., Martinka M., Welch D.R., Li G. Prognostic significance of BRMS1 expression in human melanoma and its role in tumor angiogenesis. Oncogene 2011, 30:896-906.
38. Huang H.L., Weng H.Y., Wang L.Q., Yu C.H., Huang Q.J., Zhao P.P., et al. Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis. Mol Cancer Ther 2012, 11(5):1155-1165.
39. Wade M., Li Y., Matani A., Braun S., Milanesi F., Rodewald L., et al. Functional analysis and consequences of Mdm2 E3 ligase. Oncogene 2012, 31(45):4789-4797.
40. Vassilev L.T. MDM2 inhibitors for cancer therapy. Trends Mol Med 2006, 13(1):23-30.
41. Wade M., Li Y.-Ch., Wahl G.M. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 2013, 13:83-96.
42. Nag S., Zhang X., Srivenugopal K.S., Wang M.H., Wang W., Zhang R. Targeting MDM2-p53 interaction for cancer therapy: are we there yet?. Curr Med Chem 2014, 21(5):553-574.
43. Xu C., Fan C.D., Wang X. Regulation of Mdm2 protein stability and the p53 response by NEDD4-1 E3 ligase. Oncogene 2015, 34(3):281-289.
44. Sun Y. Targeting E3 ubiquitin ligases for cancer therapy. Cancer Biol Ther 2003, 2(6):623-629.
45. Ji Z., Njauw Ch.N., Taylor M., Neel V., Flaherty K.T., Tsao H. p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. J Invest Dermatol 2012, 132:356-364.
46. Pettersson S., Sczaniecka M., McLaren L., Russel F., Gladstone K., Hupp T., et al. Non-degradative ubiquitination of the Notch1 receptor by the E3 ligase MDM2 activates the Notch signaling pathway. Biochem J 2013, 450(3):523-536.
47. Colaluca I.N., Tosoni D., Nuciforo P., Senic-Matuglia F., Galimberti V., Viale G., et al. NUMB controls p53 tumour suppressor activity. Nature 2008, 451:76-80.
48. Sun Y., Klauzinska M., Lake R.J., Lee J.M., Santopietro S., Raaf A., et al. Trp53 regulates Notch4 signaling through Mdm2. J Cell Sci 2010, 124:1067-1076.
49. Sczaniecka M., Gladstone K., Pettersson S., McLaren L., Huart A.S., Wallace M. MDM2 protein-mediated ubiquitination of NUMB protein identification of a second physiological substrate of MDM2 that employs a dual-site docking mechanism. Biol Chem 2012, 287(17):14052-14068.
50. Li Q., Lozano G. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res 2012, 19(1):1-8.
51. Panayi N.D., Mendoza E.E., Breshears E.S., Burd R. Aberrant death pathways in melanoma, recent advances in the biology, therapy and management of melanoma 2013, D. Lester (Ed.).
52. Sun Y. E3 ubiquitin ligases as cancer targets and biomarkers. Neoplasia 2006, 8(8):645-654.
53. Rajabi P., Karimian P., Heidarpour M. The relationship between MDM2 expression and tumor thickness and invasion in primary cutaneous malignant melanoma. J Res Med Sci 2012, 7(5):452-455.
54. Müller C.S. Notch signaling and malignant melanoma. Adv Exp Med Biol 2012, 727:258-264.
55. Zhao Y., Sun Y. Cullin-RING ligases as attractive anti-cancer targets. Curr Pharm Des 2013, 19(18):3215-3225.
56. Tovar Ch., Rosinski J., Filipovic Z., Higgins B., Kolinsky K., Hilton H., et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. PNAS 2006, 103(6):1888-1893.
57. Yang Y., Ludwig R.L., Jensen J.P., Pierre S.A., Medaglia M.V., Davydov I.V., et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 2005, 7:547-559.
58. Peirce S.K., Findley H.W. Targeting the MDM2-p53 interaction as a therapeutic strategy for the treatment of cancer. Cell Health Cytoskeleton 2010, 2:49-58.
59. Maerken T.V., Rihani A., Goethem A.V., De Paepe A., Speleman F., Vandesompele J. Selective inhibition of the p53-MDM2 interaction by nutlin drugs: a new therapeutic perspective for neuroblastoma. Belg R Acad Med 2013, 2:198-207.
60. Brennan R.C., Federico S., Bradley C., Zhang J., Flores-Otero J., Wilson M., et al. Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a. Cancer Res 2011, 71(12):4205-4213.
61. Secchiero P., Melloni E., di Iasio M.G., Tiribelli M., Rimondi E., Corallini F., et al. Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. Blood 2009, 113:4300-4308.
62. Metzger M.B., Hristova V.A., Weissman A.M. HECT and RING finger families of E3 ubiquitin ligases at a glance. J Cell Sci 2012, 125:531-537.
63. Huang L., Yan Z., Liao X., Li Y., Yang J., Wang Z.-G., et al. The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo. PNAS 2011, 108(29):12001-12006.
64. Marine J.C. MDM2 and MDMX in cancer and development. Curr Top Dev Biol 2011, 94:45-75.
65. Herman A.G., Hayano M., Poyurovsky M.V., Shimada K., Skouta R., Prives C., et al. Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay. Cancer Discov 2011, 1(4):312-325.
66. Wang Ch.-L., Wang J.Y., Liu Z.Y., Ma X.M., Wang X.W., Jin H., et al. Ubiquitin-specific protease 2a stabilizes MDM4 and facilitates the p53-mediated intrinsic apoptotic pathway in glioblastoma. Carcinogenesis 2014, 35(7):1500-1509.
67. Carrillo A.M., Bouska A., Arrate M.P., Eischen C.M. Mdmx promotes genomic instability independent of p53 and Mdm2. Oncogene 2014, (March). 10.1038/onc.2014.27.
68. Bernal F., Wade M., Godes M., Davis T.N., Whitehead D.G., Kung A.L., et al. A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell 2010, 18(5):411-422.
69. Chang Y.S., Graves B., Guerlavais V., Tovar Ch., Packman K., To K.-H., et al. Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. PNAS 2011, 108(29):12001-12006.
70. Gembarska A., Luciani F., Fedele C., Russell E.A., Dewaele M., Villar S., et al. MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med 2012, 18(8):1239-1247.
71. Tan M., Zhao Y., Kim S.J., Liu M., Jia L., Saunders T.L., et al. SAG/RBX2/ROC2 E3 ubiquitin ligase is essential for vascular and neural development by targeting NF1 for degradation. Dev Cell 2011, 21:1062-1076.
72. Gu Q., Bowden T.G., Normolle D., Sun Y. SAG/ROC2 E3 ligase regulates skin carcinogenesis by stage dependent targeting of c-Jun/AP1 and IkB/NF-kB. J Cell Biol 2007, 178:1009-1023.
73. Jia L., Yang J., Hao X., Zheng M., He H., Xiong X., et al. Validation of SAG/RBX2/ROC2 E3 ubiquitin ligase as an anticancer and radiosensitizing target. Clin Cancer Res 2010, 16:814-824.
74. Nai G., Marques M. Role of ROC1 protein in the control of cyclin D1 protein expression in skin melanomas. Pathol Res Pract 2011, 207:174e181.
75. Jia L., Sun Y. SCF E3 ubiquitin ligases as anticancer targets. Curr Cancer Drug Targets 2011, 11(3):347-356.
76. Sarikas A., Hartmann T., Pan Z.-Q. The cullin protein family. Genome Biol 2011, 12:220.
77. Marin I. Diversification of the cullin family. BMC Evol Biol 2009, 9:267.
78. Lee J., Zhou P. Cullins and cancer. Genes Cancer 2010, 1(7):690-699.
79. Laszlo G.S., Cooper J.A. Restriction of Src activity by Cullin-5. Curr Biol 2009, 19(2):157-162.
80. Zhang G., Li G. Novel multiple markers to distinguish melanoma from dysplastic nevi. PLoS ONE 2012, 7(9):e45037.
81. Chen G., Li G. Increased Cul1 expression promotes melanoma cell proliferation through regulating p27 expression. Int J Oncol 2010, 37:1339-1344.
82. Cheng F., He R., Zhang L., Li H., Zhang W., Ji X., et al. Expression of neddylation-related proteins in melanoma cell lines and the effect of neddylation on melanoma proliferation. Oncol Lett 2014, 7:1645-1650.
83. Jackson S., Xiong Y. CRL4s: the CUL4-RING E3 ubiquitin ligases. Trends Biochem Sci 2009, 34(11):562-570.
84. Du W., Mei Q. Ubiquitin-proteasome system, a new anti-tumor target. Acta Pharmacol Sin 2013, 34:187-188.